34th Annual Meeting European Society for Hyperthermic Oncology

September 14–17, 2022 • Gothenburg/Sweden

34th Annual Meeting European Society for Hyperthermic Oncology

September 14–17, 2022 • Gothenburg/Sweden

Conference Details

Print-File

Industrial Exhibition

Von Ardenne Institut für Angewandte Medizinische Forschung GmbH
Dresden/DE

Von Ardenne Institute of Applied Medical Research was founded more than 30 years ago to advance the medical research in the field of hyperthermia and honor the lifetime achievements of Prof. Manfred von Ardenne. 
Our institute is well-known for its pioneering work in research, development, and distribution of whole-body hyperthermia devices.
In addition, we are also active in the research of Oxygen Multistep Therapy and other medical technology applications.


heckel medizintechnik GmbH
Esslingen/DE

Since 1995 heckel medizintechnik GmbH Esslingen/Germany has established itself as a pioneer in hyperthermia. In a strategic partnership with medical device manufacturer and specialist in water-filtered infrared A technique, Hydrosun Medizintechnik GmbH Müllheim, heckel offers:

Whole-Body Hyperthermia (WBH) system heckel-HT3000 for the systemic elevation of core body temperature to mild (approx. 38.5°C), fever-range (38.5-40.5°C) or extreme levels (up to 42°C). Our focus is on fever-range WBH to stimulate anti-tumour immune effects and induce chances in tumour perfusion as adjunctive therapy in cancer treatments. In addition to its use in oncology, heckel WBH systems are used in the treatment of chronic inflammation, chronic infection and musculoskeletal pain. A strong anti-depressive effect has been confirmed in a RCT.

The Thermography-controlled, Water-filtered infrared A superficial Hyperthermia device hydrosun-TWH1500 is a world-first device for contact-free superficial hyperthermia. It has the ability to treat large areas independent of heterogeneous body contours. Continuous real-time thermographic control with automatic off/on switch allows for an optimal and safe energy input. The patient does not suffer from any physical restriction or painful applicator contact, as may be experienced for example with ulcerated lesions. The risk of acute thermal skin damage has been reduced to almost 0% even in difficult areas (e.g., tissue transfer).